Abstract
295 Novel T-cell immunotherapeutics enable the selective generation of more potently cytotoxic CD19 chimeric antigen receptor T-cells (CAR-T cells) from CMV-specific cytotoxic T-cells
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have